Metformina + Sitagliptina Anova

Metformin hydrochloride and sitagliptin, the active ingredient in Metformina + Sitagliptina Anova, is a biguanide/DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults when diet, exercise, and monotherapy are insufficient.

GNH USA supplies Metformina + Sitagliptina Anova as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformina + Sitagliptina Anova is used in the treatment of type 2 diabetes mellitus, targeting hyperglycaemia through complementary mechanisms. - Type 2 diabetes mellitus: improves overall glycaemic control when combined with diet and exercise. - Inadequate control on metformin alone: provides additional glucose‑lowering effect as part of combination therapy. - Adults requiring dual therapy: offers a single‑pill option to simplify regimens and enhance adherence.

The following adverse reactions have been reported with the metformin/sitagliptin combination.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhoea. - Headache: mild to moderate intensity. - Mild hypoglycaemia: especially when used with insulin secretagogues. - Upper respiratory tract infection: transient symptoms.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening metabolic complication. - Severe hypoglycaemia: can occur with concomitant sulfonylureas or insulin. - Pancreatitis: acute inflammation of the pancreas requiring urgent care. - Allergic reactions: rash, angio‑edema, or anaphylaxis. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, consider the following precautions. - Renal function assessment: avoid use in severe renal impairment (eGFR <30 mL/min/1.73 m²). - Hepatic function monitoring: use with caution in patients with liver disease. - Lactic acidosis risk: discontinue promptly if symptoms of metabolic acidosis develop. - Pregnancy and lactation: only if the potential benefit justifies the potential risk to the fetus or infant. - Drug interaction review: evaluate concomitant medications that may affect glucose levels or renal clearance. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Metformina + Sitagliptina Anova may interact with several drug classes.

Major Interactions (Avoid): - Cimetidine: can increase metformin plasma concentrations. - Iodinated contrast agents: risk of acute kidney injury, may precipitate lactic acidosis. - Insulin secretagogues (e.g., sulfonylureas): heightened risk of severe hypoglycaemia. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise sitagliptin levels. - Alcohol excess: potentiates metformin‑associated lactic acidosis.

Moderate Interactions (Monitor Closely): - Diuretics (thiazides): may affect renal clearance of metformin. - ACE inhibitors/ARBs: monitor renal function and electrolytes. - Beta‑blockers: can mask hypoglycaemia symptoms. - Warfarin: occasional alterations in INR, require monitoring.